BLU-5937 is a highly selective P2X3 antagonist currently being investigated for the treatment of chronic cough. touchRESPIRATORY were delighted to speak with Professor Alyn Morice (Hull York Medical School, University of Hull, Castle Hill Hospital, Yorkshire, UK) around the challenges and unmet needs in the treatment of refractory chronic cough and the aims, design and patient characteristics of the patients enrolled in the Phase 2b study (ClinicalTrials Identifier: NCT04678206).
The abstract ‘Characteristics of Participants with Refractory Chronic Cough Enrolled in A Phase 2b Trial of BLU-5937.’ (Abstract number: PA178) was presented at ERS 2022, 4–6 September, 2022.
- What are the challenges and unmet needs in the treatment of refractory chronic cough? (0:12)
- What is BLU-5937 and what is the rationale for its use in refractory chronic cough? (1:28)
- What are the aims and design of the Phase 2b study? (2:09)
- What were the patient characteristics of patients enrolled in this trial? (4:57)
- When are results from the phase 2b study expected? (6:04)
Disclosures: Alyn Morice discloses consulting for MSD; receiving grant/ research support from Merck; serving on advisory boards for MSD; receiving honoraria from MSD; and participating in speaker’s bureaus for MSD.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
Share this Video
Related Videos In Chronic Cough
Alan Kaplan: The IPCRG Sentinel Network and Respiratory Q&A
We were delighted to meet with Prof. Alan Kaplan (University of Toronto, Toronto, ON, Canada) to discuss the international IPCRG Sentinel Network which represents each continent and includes over 100 primary care clinicians. The IPCRG is providing answers based on published peer reviewed evidence to COVID and respiratory questions from the Sentinel Network. Questions Could […]
James Wingfield Digby, ERS 2022: Hypotonic Saline in the Diagnosis of Refractory/Unexplained Chronic Cough
Chronic cough is a persistent cough lasting ≥8 weeks and is estimated to affect between 2-18% of the global population; however chronic cough is often unrecognized, underdiagnosed and there remain many unmet needs in its treatment. It was a pleasure to speak with Dr. James Wingfield Digby (University of Manchester, Manchester, UK) around his study […]
James Wingfield Digby, ERS 2022: Low-dose Opiates for Refractory/Unexplained Chronic Cough
Chronic cough is a persistent cough lasting ≥8 weeks and is estimated to affect between 2-18% of the global population. touchRESPIRATORY were delighted to speak with Dr. James Wingfield Digby (University of Manchester, Manchester, UK) around the aims and design of the real world study investigating low-dose opiates in the treatment of chronic cough and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!